Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up results from CheckMate 649.

被引：0

作者：

Janjigian, Yelena Y.

Moehler, Markus H.

Ajani, Jaffer A.

Shen, Lin

Garrido, Marcelo

Gallardo, Carlos

Wyrwicz, Lucjan

Yamaguchi, Kensei

Cleary, James M.

Elimova, Elena

Bruges, Ricardo Elias

Karamouzis, Michalis

Skoczylas, Tomasz

Bragagnoli, Arinilda

Liu, Tianshu

Tehfe, Mustapha

McCraith, Stephen

Hu, Nan

Zhang, Jennifer

Shitara, Kohei

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Weill Cornell Med Coll, New York, NY USA

[3] Johannes Gutenberg Univ Mainz, D-55131 Mainz, Germany

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[5] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China

[6] Pontificia Univ Catolica, Santiago, Chile

[7] Fdn Arturo Lopez Perez, Providencia, Chile

[8] Narodowy Inst Onkol, Klin Onkol & Radioterapii, Warsaw, Poland

[9] Canc Inst Hosp JFCR, Tokyo, Japan

[10] Dana Farber Canc Inst, Boston, MA USA

[11] Princess Margaret Canc Ctr, Toronto, ON, Canada

[12] Inst Nacl Cancerol ESE, Bogota, Colombia

[13] Laiko Gen Hosp Athens, Athens, Greece

[14] Med Univ Lublin, Klin Chirurgii Ogolnej Gastroenterol & Nowotworow, Lublin, Poland

[15] Fundacao Pio XII, Barretos, Brazil

[16] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China

[17] Ctr Hosp Univ Montreal, Montreal, PQ, Canada

[18] Bristol Myers Squibb, Princeton, NJ USA

[19] Natl Canc Ctr Hosp East, Kashiwa, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期

关键词：

D O I：

10.1200/JCO.2025.43.4_suppl.398

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：398 / 398

页数：1

共 50 条

[41] Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Interim results of nivolumab plus chemotherapy (N plus C) versus (C) from CheckMate 649
Moehler, M.
Elimova, E.
Blum, S., I
Xiao, H.
Davenport, E.
Wang, J.
Hunter, S.
Li, M.
Kondo, K.
Wyrwicz, L.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 214 - 215
[42] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Patient reported outcomes (PRO) in the Asian subgroup of the RATIONALE-305 study
Kato, K.
Xu, R-H.
Oh, D-Y.
Bai, Y.
Shi, J.
Lee, K-W.
Hirano, H.
Xu, H.
Sheng, T.
Barnes, G.
ANNALS OF ONCOLOGY, 2024, 35 : S1456 - S1456
[43] Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
Moehler, Markus H.
Kato, Ken
Arkenau, Hendrik-Tobias
Oh, Do-Youn
Tabernero, Josep
Cruz-Correa, Marcia
Wang, HongWei
Xu, Hui
Li, Jiang
Yang, Silu
Xu, Rui-hua
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 286 - 286
[44] Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227
Schumann, C.
Paz-Ares, L.
Ciuleanu, T. -E
Lee, J. -S
Urban, L.
Caro, Bernabe R.
Park, K.
Sakai, H.
Ohe, Y.
Nishio, M.
Pluzanski, A.
Ramalingam, S. S.
Brahmer, J. R.
Borghaei, H.
O'Byrne, K. J.
Hellmann, M. D.
Memaj, A.
Bushong, J.
Tran, P.
Reck, M.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 173 - 173
[45] TREATMENT PATTERNS AND PERFORMANCE STATUS IN UNRESECTABLE ADVANCED OR METASTATIC (ADV/MET) GASTRIC CANCER (GC), GASTROESOPHAGEAL JUNCTION CANCER (GEJC) AND ESOPHAGEAL ADENOCARCINOMA (EAC) PATIENTS RECEIVING FIRST LINE (1L) TREATMENT
Hall, J.
Khela, K.
Middleton-Dalby, C.
Bertwistle, D.
Xiao, H.
VALUE IN HEALTH, 2020, 23 : S485 - S485
[46] Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/ gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): 36-month results of nivolumab plus chemotherapy (N plus C) versus (C) from CheckMate 649
Elimova, Elena
Wyrwicz, Lucjan
Chen, Clara
Blum, Steven Michael
Davenport, Eric
Wang, Jinyi
Kondo, Kaoru
Moehler, Markus H.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[47] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Health-related quality of life (HRQoL) outcomes in the RATIONALE-305 study.
Cruz-Correa, Marcia
Xu, Rui-Hua
Moehler, Markus H.
Oh, Do-Youn
Kato, Ken
Spigel, David R.
Arkenau, Hendrik-Tobias
Tabernero, Josep
Zimina, Anastasia V.
Bai, Yuxian
Shi, Jianhua
Lee, Keun-Wook
Hirano, Hidekazu
Wyrwicz, Lucjan S.
Pazo Cid, Roberto
Xu, Hui
Sheng, Tao
Barnes, Gisoo
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 290 - 290
[48] Nivolumab (NIVO) plus (+) chemotherapy (chemo) or ipilimumab (IPI) vs chemo as 1L treatment for advanced esophageal squamous cell carcinoma (ESCC): First comprehensive biomarker analyses from CheckMate 648.
Lei, Ming
Doki, Yuichiro
Kitagawa, Yuko
Kato, Ken
Chau, Ian
Yao, Jin
Xu, Jianming
Wyrwicz, Lucjan S.
Motoyama, Satoru
Ogata, Takashi
Kawakami, Hisato
Hsu, Chih-Hung
Adenis, Antoine
El Hajbi, Farid
Di Bartolomeo, Maria
Braghiroli, Maria Ignez
Holtved, Eva
Blum Murphy, Mariela A.
Novosiadly, Ruslan
Ajani, Jaffer A.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 252 - 252
[49] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648.
Chau, Ian
Ajani, Jaffer A.
Doki, Yuichiro
Xu, Jianming
Wyrwicz, Lucjan
Motoyama, Satoru
Ogata, Takashi
Kawakami, Hisato
Hsu, Chih-Hung
Adenis, Antoine
El Hajbi, Farid
Di Bartolomeo, Maria
Braghiroli, Maria Ignez Freitas Melro
Holtved, Eva
Murphy, Mariela A. Blum
Abdullaev, Sandzhar
Soleymani, Samira
Lei, Ming
Kato, Ken
Kitagawa, Yuko
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[50] First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced gastroesophageal junction cancer (GEJC) and esophageal adenocarcinoma (EAC): Analysis of KEYNOTE-590 and KEYNOTE-859 by tumor type.
Shiu, Kai-Keen
Rivera, Fernando
Medley, Louise C.
Aghmesheh, Morteza
Dunne, Richard Francis
Roy, Rajarshi
Wyrwicz, Lucjan S.
Larson, Timothy
Metges, Jean-Philippe
Mansoor, Wasat
Goekkurt, Eray
Moreira Antunes, Luiz Carlos
Castro Oliden, Victor
Jensen, Erin
Shah, Sukrut
Bordia, Sonal
Bhagia, Pooja
Lowery, Maeve Aine
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 345 - 345

← 1 2 3 4 5 →